Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx (Nasdaq: CDNA) will present 40 scientific abstracts at the 2021 American Transplant Congress (ATC) and host two symposia showcasing advancements in the clinical utility of AlloSure. Key studies highlighted include ADMIRAL and KOAR, focusing on donor-derived cell-free DNA in transplant recipients. The first symposium covers AlloSure's utility in heart, lung, and liver transplants, while the second presents findings from the ADMIRAL study and one-year data from the KOAR study, aimed at improving patient care in kidney transplants.
CareDx, Inc. (Nasdaq: CDNA) announced a strategic partnership with OrganX to develop clinical decision support tools for transplant patients. This collaboration aims to integrate AlloSure, a dd-cfDNA assay, with large transplant databases, providing innovative analytics for organ injury assessment. CareDx's CEO highlighted that this partnership will enhance its leadership in multi-modality testing. OrganX's founder emphasized their shared goal of improving patient quality of life through advanced digital health solutions. The collaboration presents promising benefits but also carries inherent risks, as noted in CareDx's forward-looking statements.
CareDx, a precision medicine company, announced its participation in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 8, 2021. The event will feature a management presentation scheduled for 1:40 p.m. Pacific time / 4:40 p.m. Eastern time. Investors can listen to the live webcast through CareDx’s investor relations page. CareDx specializes in high-value healthcare solutions for transplant patients and their caregivers.
CareDx, Inc. (CDNA) has initiated the Molecular Assessment and Profiling of Liver Transplant Recipients (MAPLE) Study at Mount Sinai Hospital, enrolling the first patient. This multi-center study will evaluate the LiverCare platform, which utilizes various testing methodologies including donor-derived cell-free DNA and gene expression profiling to assess liver allograft status. The study aims to enroll 1500 liver transplant recipients and underscores CareDx's commitment to advancing care in transplant medicine.
CareDx, Inc. (Nasdaq: CDNA) announced a minority investment in Miromatrix, a biotech firm focused on developing bioengineered organs to reduce the transplant waiting list. This collaboration will leverage CareDx's technology for research and development initiatives. The significant shortage of available organs impacts thousands annually, with over 40,000 kidney patients dying each year due to this crisis. Miromatrix's patented technology aims to create fully implantable organs like livers and kidneys, aligning with CareDx's mission to enhance transplant patient care.
CareDx, a precision medicine company focused on healthcare solutions for transplant patients, announced its participation in the Jefferies Virtual Healthcare Conference. The event will take place on June 1, 2021, at 10:00 a.m. PT / 1:00 p.m. ET. Investors can access the live webcast through the investor relations section of CareDx's website. CareDx specializes in testing services and digital solutions along the transplant patient journey, making it a leading provider of genomics-based information for transplant care.
CareDx Announces Innovations in Kidney Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA) will showcase advancements in donor-derived cell-free DNA (dd-cfDNA) at the 3rd Annual Global Kidney Innovations Summit on May 13-14, 2021. Reg Seeto, President and CEO, will present on May 14, discussing AlloSure, a blood test that significantly improves organ rejection detection post-transplant. The summit, organized by the American Association of Kidney Patients, aims to enhance global kidney health awareness and innovation.
CareDx reported strong first-quarter results for 2021, achieving $67.4 million in revenue, a 76% increase year-over-year. The company provided around 33,200 AlloSure and AlloMap patient results, with over 60 U.S. transplant centers adopting AlloSure Kidney protocols. A successful public offering raised approximately $188.7 million, boosting total cash and equivalents to $374.3 million. CareDx has increased its full-year revenue guidance to between $270 million and $280 million, reflecting continued growth in the transplant ecosystem.
CareDx, Inc. (Nasdaq: CDNA) announced the presentation of 15 heart abstracts at the ISHLT Annual Meeting on April 24-28, 2021. The company will showcase a total of 22 abstracts, reflecting its leadership in cardiothoracic care. Notably, a virtual symposium titled “HeartCare: The Utility of Multi-Modality in Transplant Patient Care” will occur on April 25 from 11:30 a.m. to 12:30 p.m. Eastern Time. Presented by experts, the research emphasizes innovative diagnostics for heart transplant rejection detection.
CareDx, Inc. (Nasdaq: CDNA) has announced that Medicare coverage for its transplant testing services remains unchanged under a new universal coverage policy by Palmetto MolDx. The policy reaffirms patient access to services essential for managing organ transplant care. CareDx’s AlloMap and AlloSure tests, which are critical for identifying organ rejection, have been validated through rigorous studies. This continued coverage supports CareDx's mission in enhancing patient care and solidifies its role as a leader in precision medicine.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
